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Abstract
Introduction: This article is based on Clinical Guidelines for obstruc-
tive sleep apnoea (OSA) established by a taskforce coordinated by the 
Brazilian Sleep Association. 
Objective: The aim of this article is to evaluate the available scien-
tific evidence regarding the efficacy, adherence and safety of using 
mandibular advancement devices (MAD) as a therapeutic course for 
treating obstructive sleep apnoea in adult patients. 
Method: Active searches were performed in the PubMed/MEDLINE, 
EMBASE, Scielo/LILACS and Cochrane Library databases. Methodolo-
gical aspects were used to rank the levels of evidence according to the 
criteria of the Centre for Evidence-Based Medicine at Oxford. 
Results: Mandibular advancement devices offer the best results for 
patients with primary snoring, upper airway resistance syndrome and 
mild or moderate OSA (Levels of Evidence I and II). Continuous positive 
airway pressure (CPAP) is more effective in controlling OSA (Level of 
Evidence I). However, patients seem to exhibit greater adherence to 
oral appliances (MAD) than (CPAP) devices. The long-term side effects 
most observed after the use of MADs are related to changes in the 
mandibular and dental positions (Levels of Evidence I and II). 
Conclusion: MAD constitute a therapeutic alternative for OSA and 
promote favourable results with good efficacy and adherence to 
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Introduction
Obstructive Sleep Apnoea (OSA) is characterized by 
upper airway obstruction events during sleep in the 
presence of respiratory movements. This obstruction 
is manifested as recurrent, involving an awakening 
due to increased respiratory effort, limitation, re-
duction (hypopnea), or complete cessation (apnea) 
of airflow. It is the most prevalent disorder among 
respiratory sleep disorders, being more prevalent in 
males and increased with increasing age. OSA pre-
valence is also greater in obese men and women [1].
Patients with untreated OSA have more cardio-
vascular events when compared to treated patients. 
OSA is now recognized as an independent risk 
factor for developing comorbidities and increased 
mortality [2]. It has even been suggested that OSA 
should be considered a systemic disorder and not 
just a disorder of the upper airways (UAW). The 
systemic impact may involve cardiovascular and me-
tabolic consequences [3]. 
OSA is one of many obstructive respiratory disor-
ders during sleep; however, these disorders are not 
limited only to patients who suffer typical OSA; ins-
tead, they are included on a continuum that ranges 
from snoring until OSA. Upper Airway Resistance 
Syndrome (UARS) was initially described by Guille-
minault et al. in 1993 [4]. This syndrome was des-
cribed based on the assumption that the repetitive 
increase in respiratory effort during sleep, in the 
absence of apneic and hypopneic events, will induce 
arousals that can lead to excessive daytime slee-
piness and functional symptoms and is associated 
with cognitive and cardiovascular morbidity [5]. De-
finitions of sleep-related respiratory disorders, pu-
blished by the taskforce of the American Academy 
of Sleep Medicine (AASM) in 1999 did not include 
UARS but described respiratory effort-related arou-
sals (RERA). Thus, the International Classification of 
Sleep Disorders (ICSD-III) recommends that UARS 
still be included as part of OSA rather than as a 
separate entity [6]. 
OSA is considered mild when daytime sleepiness 
or involuntary sleep episodes occur during activities 
that require little attention, such as watching TV, 
reading or riding in a vehicle as a passenger. At 
this degree of the disorder, the symptoms produce 
discreet changes in social or occupational functions. 
On a polysomnogram, the apnea and hypopnea in-
dex (AHI) is greater than or equal to 5 and less than 
or equal to 15 per hour of sleep. 
When OSA is moderate, drowsiness or involuntary 
sleep episodes occur during activities that require 
some attention, such as attending social events. The 
symptoms produce changes in social or occupatio-
nal functions. The AHI is greater than 15 and less 
than or equal to 30 per hour sleep. 
In severe OSA, daytime sleepiness or involuntary 
sleep episodes occur during activities that require 
greater attention, such as eating, talking, walking 
or driving. The symptoms cause marked changes in 
social or occupational functions. The AHI is usually 
greater than 30 per hour of sleep [6-8].
OSA treatment includes clinical and surgical 
modalities. Surgery is nowadays not often indica-
ted, and among clinical managements CPAP and 
Mandibular advancement devices (MAD) are the 
treatment. Side effects can arise in the short, medium or long term. 
Patients must be informed about the possible occurrence of these 
adverse effects, and the orthodontist must be able to manage any 
side effects that occur due to the use of these devices. 
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most used modalities due to their research results 
in literature. CPAP is the gold standart treatment, 
but its acceptance and compliance is low, and Oral 
Appliance (OA) treatment has a better compliance 
than CPAP.
Mandibular advancement devices (MAD) prevent 
collapse of the oropharynx tissues and represents 
a potentially important therapy for OSA patients. 
However, the clinical applicability regarding effecti-
veness, adherence and side effects still need to be 
elucidated [9]. 
The text of the present article is based on Clinical 
Guidelines for OSA established by a taskforce coor-
dinated by the Brazilian Sleep Association. The goal 
of this article is to evaluate the scientific evidence 
on the efficacy, adherence and safety (i.e., possible 
damage caused by therapy and/or side effects) of 
using MAD as a therapeutic course for OSA. 
Methods
Active searches were performed in the PubMed/
MEDLINE, EMBASE, Scielo/LILACS and Cochra-
ne Library databases using the following search 
terms: (Oral OR Orally OR Intraoral OR dental OR 
Tooth) AND (Appliance OR Appliances OR Devices 
OR Device) AND (“sleep apnea, obstructive”[MeSH 
Terms]) OR (Apnea Obstructive Sleep) OR (Apneas 
Obstructive Sleep) OR (Obstructive Sleep Apneas) 
OR (Sleep Apneas Obstructive) OR (Syndrome 
Sleep Apnea Obstructive) OR (Sleep Apnea Syndro-
me Obstructive) OR (Syndrome Obstructive Sleep 
Apnea) OR (Obstructive Sleep Apnea) OR (Obs-
tructive Sleep Apnea Syndrome) OR (Upper Airway 
Resistance Sleep Apnea Syndrome) OR (Syndrome 
Upper Airway Resistance Sleep) AND (randomized 
controlled trial [pt]) OR (controlled clinical trial [pt]) 
OR (randomized [tiab]) OR (placebo [tiab]) OR (drug 
therapy [sh]) OR (randomly [tiab]) OR (trial [tiab]) 
OR (groups [tiab]) AND (humans[mh]).
Table 1. Research question.
Does the intervention work? 
Benefits of a treatment
Level 
I1
Systematic review of randomized 
controlled clinical trials or n-of-1 
trials.3
Level 
II1
Randomized controlled clinical 
trial or observational study with 
significant magnitude of the 
estimate
Level 
III1
Non-randomized controlled studies 
(cohort)/follow-up studies2
Level 
IV1
Case series, case-control studies or 
controlled studies with historical 
comparisons2
Level 
V1
Mechanism-based reasoning 
(biological plausibility)
Table 2.  Possible damages associated with the therapy used.
What are the most common damages?
Damages associated with treatment
Level 
I1
Systematic review of randomized controlled clinical trials, systematic 
review of nested case-control studies, n- of-1 trials, with a patient 
suffering a clinical situation in question, or an observational study with 
significant magnitude of effects
Level 
II1
Individual randomized controlled studies or, exceptionally, observational 
studies with significant magnitude of the estimate
Level 
III1
Non-randomized controlled studies (cohort)/follow-up studies (post-
marketing surveys) with sufficient sampling power to rule out common 
damages (for long-term damages, the follow-up period should be 
sufficiently long)2
Level 
IV1
Case series, case-control studies or studies with a historical control2
Level 
V1
Mechanism-based reasoning (biological plausibility)
1:  The level of evidence can vary depending on the quality of the study, the accuracy, the agreement among the available studies, the magnitude of the estimate, 
and the directness of the evidence [indirect evidence is that where one or more elements of the research question do not fully match the desired items of the 
research question]. 
2: A systematic review is generally more reliable than an individual study. 
3:  n-of-1 trials: randomized and blinded (using masking) trials in which a single patient suffers a series of treatment pairs composed of an active treatment 
and a placebo (or alternative) per pair, with the other pair determined by random allocation. Appropriate treatment goals (i.e., signs, symptoms, laboratory 
indicators) are used as measures of efficacy. The trial continues until the efficacy is established or disproven.
Source: OCEBM Levels of Evidence Working Group*. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. 
http://www.cebm.net/index.aspx?o=5653
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Specific methodology was used in an attempt to 
identify data on the efficacy and safety of inter-
vention (therapy with Oral Appliance-OA), ranking 
the levels of evidence according to the criteria of 
the Centre for Evidence-Based Medicine at Oxford. 
The following instrument was used to classify the 
evidence (Table 1 and 2). 
Oral Appliances (OA) 
OA are used in the oral cavity during sleep to pre-
vent collapse of the oropharynx tissues, thereby 
reducing obstructive events in the upper airways 
(UAW).
Currently there are numerous devices with diffe-
rent designs and materials, which fit into two main 
categories: tongue-retaining devices (TRD) (Figure 
1) and mandibular advancement devices (MAD) or 
mandibular repositioners (Figure 2). Mandibular 
repositioning appliances have the largest number 
of publications because tongue retainers are less 
commonly used and, for this reason, little studied. 
Therefore, only MADs will be addressed in terms of 
their efficacy, adherence and safety. 
Efficacy of MAD in sleep parameters and 
excessive sleepiness 
A Cochrane systematic review, published in 2006 
[10], and another published in 2011 [11] demonstrate 
that there is growing scientific evidence suggesting 
that treatment with MADs improves the subjective 
symptoms of drowsiness and significantly reduces 
the respiratory abnormal events during sleep (AHI 
and minimum oxyhemoglobin saturation) in pa-
tients with OSA compared with a placebo device. 
According to these studies, treatment with MADs 
is indicated for patients with snoring, upper airway 
resistance syndrome (which most researchers con-
sider an initial stage of OSA) and mild OSA (Level 
of Evidence I). 
When treatment with MADs is compared to 
CPAP (Continuous Positive Airway Pressure – de-
vices that use positive-pressure ventilation in the 
airways), the literature shows that CPAP is more 
effective for improving respiratory parameters 
of sleep (AHI and oxyhemoglobin saturation), 
although improvement in excessive daytime slee-
piness (SDE) is similar between the two treatments 
(Level of Evidence I) [10, 12]. The authors also warn 
that the number of randomized trials with appro-
priate duration and sample size is still insufficient 
and suggested future studies on the efficacy aga-
inst excessive drowsiness (Level of Evidence I) [10]. 
It has been suggested that the absence of diffe-
rence in improved drowsiness over the long-term 
between MAD and CPAP groups may indicate that 
the greater reduction in the AHI values for the 
CPAP group may not be clinically relevant (Level 
Evidence II) [13]. 
A single trial comparing MAD with a surgical pro-
cedure suggests that the OA was more effective 
Figure 1: Tongue-retaining device (TRD).
Figure 2:  Mandibular advancement device (man-
dibular repositioner) (MAD).
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than uvulopalatopharyngoplasty (UPPP) for impro-
ving rates of sleep respiratory events (Level of Evi-
dence II) [14]. 
We must remember that there are many aspects 
that interfere with the efficacy of treatment with 
OA. One of the most important factors is the design 
of the device, as demonstrated in the systematic 
review published in 2011 with mandibular reposi-
tioning (or mandibular advancement) devices. Ac-
cording to that review, there does not seem to be 
one MAD model that is better than another for 
improving sleep parameters. However, it was de-
monstrated that the efficacy of devices that advan-
ce the jaw depends on a number of factors, such 
as the OA fabrication material and manufacturing 
method (non-customized or customized), if the OA 
is of the monobloc or gradual mandibular advance-
ment type, with or without mandibular freedom of 
movement, and the degree of protrusion (sagittal 
and vertical), among other factors (Level of Evidence 
I) [11]. 
Customized oral appliance are more effective in 
the treatment of OSA than non-customized devices. 
However, it seems that among personalized devices, 
there is no significant difference in efficacy between 
different models (Level of Evidence II) [15, 16].
Predicting the success of treatment with MAD 
has been the aim of many studies. Some cephalo-
metric measurements have been described as pre-
dictors, such as smaller soft palate, greater upper 
airway space in the retropalatal region, less distance 
between the mandibular plane and the hyoid bone, 
proper SNA angle and smaller SNB angle (Level of 
Evidence IV) [17-19]. 
However, some studies contradict those findings, 
showing that the cephalometric measurements do 
not differ between patients with success or failure 
in treatment with MADs (Level of Evidence IV) [20]. 
The efficacy of treatment with MADs seems to be 
influenced by the body position, with the best re-
sults achieved in patients who suffer most events 
in supine position (Level of Evidence IV) [21, 22]. 
Women have demonstrated a greater success rate 
when using MADs versus men (Level of Evidence 
III) [23]. Cephalometric measurements are used in 
many studies due to easy access, fast analysis and 
low cost. Nevertheless, it has the limitation of being 
a two-dimensional exam.
Efficacy of MAD in cognition and quality 
of life 
A randomized clinical trial showed improvements 
in fatigue/energy levels and vigilance/psychomo-
tor speed when MADs were compared to placebo 
(Level of Evidence II) [24]. A systematic review and 
meta-analysis published in 2013 showed that the 
effects on health related to aspects of quality of life 
and cognitive performance were similar between 
MADs and CPAP (Level of Evidence I) [12]. 
A study showed that the improvement in the qua-
lity of life (Nottingham Health Profile) was greater for 
MADs compared to CPAP in various aspects, such 
as physical mobility, social isolation, pain, emotio-
nal function and sleep [25]. Thus, while treatments 
with oral appliances may not reduce AHI as much 
as CPAP, consistently and over several studies, they 
significantly improve the quality of life of individuals 
with OSA (Level of Evidence II). 
Efficacy of MAD in cardiovascular 
parameters 
It has been demonstrated that treatment with 
MADs can improve cardiovascular complications of 
OSA. A systematic review and meta-analysis publis-
hed in 2013 showed that the effects of MADs and 
CPAP were similar regarding the decrease in syste-
mic blood pressure (Level of Evidence I) [12]. 
It has also been demonstrated that the impro-
vement in blood pressure persisted over 3 years of 
treatment with MADs (Level of Evidence IV) [26]. 
Additionally, there was a positive correlation bet-
ween the decline in AHI and the reduction of sys-
temic blood pressure after treatment with MADs 
(Level of Evidence IV) [21]. 
InternatIonal archIves of MedIcIne 
sectIon: dental MedIcIne
ISSN: 1755-7682
2017
Vol. 10 No. 232
doi: 10.3823/2502
This article is available at: www.intarchmed.com and www.medbrary.com 6
Other cardiovascular outcomes have been 
evaluated, but only in a few studies. One study 
showed that blood biomarkers of oxidative stress 
and endothelial function were improved in a group 
of OSA patients treated with MADs compared to 
a reference group of patients without OSA (Level 
of Evidence IV) [27]. Interestingly, these changes 
were observed after 12 months of treatment, des-
pite the persistence of residual sleep respiratory 
events. The effects of treatment with MADs were 
also found in the autonomic nervous system, with 
improvements in heart rate variability, showing a 
modulation in autonomic nervous system (Level of 
Evidence IV) [28]. 
Adherence to MAD
A Cochrane Review published in 2006 assessed 
treatment with CPAP compared to control and 
MAD treatment. This review included 36 studies 
involving 1,718 patients and showed that although 
CPAP is better than MADs in reducing respiratory 
events on a polysomnogram, those who respon-
ded to both treatments had a strong preference 
for the MAD, which directly influences adherence 
to therapy, especially in the long term (Level of 
Evidence I) [29]. 
However, a systematic review and meta-analysis, 
published in 2013, showed that adherence, prefe-
rence and the abandonment rate were similar bet-
ween the two treatments (MADs and CPAP) (Level 
of Evidence I) [12]. 
Adherence to MADs is typically measured subjec-
tively for daily use. The adherence to MADs, moni-
tored subjectively at the beginning of the treatment, 
seems to occur in approximately 90% of patients, 
reducing to 77% at the end of one year (Level of 
Evidence V) [30]. Another study showed that 64% 
of patients continued to use MADs 5.7 years after 
installation, where the main reasons for abando-
ning treatment were: discomfort caused by MADs 
(44.4%), the absence of the desired effect (33.6%) 
and switching to CPAP treatment (23.3%). [31] That 
study found that 40% of non-adherence occurred 
in the first 6 months of using the device (Level of 
Evidence III) [31]. 
In 2000, a study used a thermosensitive battery 
placed inside the resin device to detect the use of 
the MADs through body temperature (Level of Evi-
dence IV) [32]. A similar methodology was only re-
assessed recently and is now available. That study 
showed that a thermal microsensor embedded in 
the resin of the device is a valid measure of adhe-
rence. The average usage was 6.6+1.3h per night 
in 82% of the 51 patients who regularly used the 
MADs (Level of Evidence III) [33]. Some predictors 
of adherence have been attributed to the material 
and equipment type, the presence of mandibular 
mobility and the adjustment in terms of the pro-
trusion. 
MADs personalized to the individual seem to 
promote greater adherence than non-customized 
devices (Level of Evidence II) [34]. Some surveys 
compared several device models with different re-
sults. Some authors suggest that the patient's pre-
ference in terms of the device model is important 
for adherence to treatment (Level of Evidence II) 
[35, 36]. 
Safety of using MAD
Possible side effects of treating OSA with MADs can 
occur with short-, medium- or long-term use. The 
most common and observed side effects are short- 
and medium-term effects, such as complaints of 
excessive salivation or dry mouth, followed by pain 
and/or discomfort in the support teeth, pain due 
to temporomandibular dysfunction (TMD), and pain 
and/or discomfort in intraoral soft tissue. 
In general, the side effects when MAD is well 
indicated seem to be minimal, according to most 
of the assessments found in the literature (Levels of 
Evidence I-III) [12]. 
In studies with long-term evaluations, the most 
observed side effects are related to changes in 
mandibular position and dental positions (Levels of 
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Evidence I and II) [31, 37]. Therefore, when propo-
sing this modality of treatment, patients must be 
informed about the possible occurrence of these 
adverse effects, and the orthodontist must be able 
to manage any side effects that may arise due to 
the use of OA. 
Complications from TMD can also occur, but there 
is little evidence. A randomized study assessed pain 
intensity and impairments in mandibular function 
with MAD and CPAP usage after 2 months, 1 year 
and 2 years. Treatment with MADs resulted in more 
pain from TMD than CPAP in the initial period of 
use, although this pain was transient and generally 
not severe. However, there were no limitations in 
mandibular function during the 2 years with both 
treatments. According to that study, in general, pain 
is not a reason to contraindicate MADs, and it ap-
pears that TMD and the risk of developing pain 
and changes in the function of the TM complex 
are limited with long-term MAD usage (Level of 
Evidence II) [38]. 
Results 
Growing scientific evidence suggests that treatment 
with MADs improves the subjective symptoms of 
drowsiness and significantly reduces the respiratory 
abnormal events during sleep in patients with OSA, 
significantly improving the quality of life of these 
individuals (Level of Evidence I). 
MADs yield the best results in patients with 
snoring, UARS and mild or moderate OSA (Levels 
of Evidence I and II). Although not as effective in 
controlling OSA as CPAP, patients seem to exhibit 
greater adherence to MADs (Level of Evidence I). 
When MAD usage is well indicated, the side 
effects seem to be minimal. In the long term, the 
most observed side effects are related to changes 
in mandibular position and dental positions (Levels 
of Evidence I and II). 
Future studies are needed to evaluate the best 
device design, the predictive factors for success with 
OA and the clinical efficacy and adverse effects in 
the long term. 
Discussion
According to this study, a lot of papers related an 
improvement of sleep parameters and excessive 
sleepiness with MADs treatment. A recent paper re-
vealed similar data with significant changes in Sno-
re index, Apnea-hypopnea index, oxygen saturation 
and sleepiness (Epworth Sleepiness Scale) [39]. Im-
provements in cognitive performace and quality of 
life, as well as a reduction in risk of cardiovascular 
events, were also observed in the present study. 
Likewise, this result was evidenced by Galic et al 
(2016) and Anandam et al (2013) [40, 41]. 
Some reviews reported in this study showed 
substantial limitations due to the use of two-dimen-
tional (2D) cephalometry as methodology. Conven-
tional 2D lateral cephalographs provides changes in 
magnification, geometric distortion, superimposed 
structures and inconsistent head position. One of 
the key advantages of three-dimentional (3D) com-
puted tomography over 2D radiography is its abili-
ty to provide 3D volumetric, surface and sectional 
information about the craniofacial structures with 
great accuracy [42]. 
Three-dimentional upper airway changes with 
mandibular advancement device in patients with 
obstructive sleep apnea has been observed. Accor-
ding to Shete and Bhad (2017), MAD´s use increa-
ses the mean upper pharyngeal airway volume in 
this cohort. This increase in volume appeared to be 
related to increased oxygen saturation. Thus, the 
MAD’s efficacy are also observed in 3D studies [43].
Tison et al (2011), showed a satisfactory adheren-
ce and satisfaction in a population of 113 patients 
treated with MAD. The present study reported a 
similar result, with considerable adherence to the 
MAD’s use [44]. 
It was observed with this study that personali-
zed devices with gradual mandibular advancement 
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are more effective in OSA treatment than non-
customized devices. The maximum level of advan-
cement should be assessed for each case. Weekly 
adjustments are usually made until the maximum 
confortable protrusion established for each patient. 
One month after MAD collocation, patients were 
asked about the event of side effects for the use 
of MAD. Three months after MAD collocation, once 
the patient and his bed partner reported an evident 
clinical improvement, the next step is the polysom-
nography evaluation with MAD at the adequate 
advancement level [39]. 
When compared with CPAP, MAD is clinically 
effective and cost-effective in mild to moderate 
OSA. It is the appropriate first choice in most pa-
tients in the short term. Nevertheless, more studies 
should explore more additional clinical and cost be-
nefits of MADs [45]. 
Conclusions 
MADs are a therapeutic alternative for OSA and 
promote favourable results with good efficacy and 
adherence to treatment. Possible side effects can 
occur in the short-, medium- or long-term. Patients 
must be informed about the possible occurrence of 
these adverse effects, and the orthodontist must be 
able to manage any side effects that may arise due 
to the use of these devices.
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